Pharma commercial intelligence, news & analysis

Evaluate radically transforms your confidence in strategic portfolio decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

How we can help you

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview.

OUR PRODUCTS

EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the only single view of the risk and return of the R&D landscape from EvaluatePharma Vision.

OUR SERVICES

Custom Solutions

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

January 24, 2020

Ipsen’s quick fix backfires

A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.